Deterioration of Brain Cell Function Induced by Dapoxetine Administration in Male Rats

Marwa AM*, Sayed O, El-Hanbuli HM, Abo-sief AF

1 Lecturer of Forensic Medicine and Clinical Toxicology, Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Fayoum University, Fayoum, KimanFaris Str., Egypt.
2 Lecturer of Chemistry, Department of Chemistry, BioChemistry Division, Faculty of Science, Fayoum University, KimanFaris Str., Egypt.
3 Assistant Professor of Pathology, Department of Pathology, Faculty of Medicine, Fayoum University, KimanFaris Str., Egypt.
4 Lecturer of Andrology, Department of Andrology, Sexology & STDs, Faculty of Medicine, Beni-Suef University, Salah Salem Str., Egypt.

Abstract

Background and Aim of Work: Dapoxetine is a Selective Serotonin Reuptake Inhibitor (SSRI) decided for the remedy of premature ejaculation (PE) in adult men. The objective of this research was to determine the influence of dapoxetine on the brain of male rats.

Methods: The rats were divided into three empirical groups and one control group of 10 rats each. The empirical groups daily took dapoxetine hydrochloride at doses of 2.0, 4.0 or 8.0 mg/kg (each dose for each group). 1 in 0.5 ml saline for 60 days. Results: There was a significant elevation in lipid peroxidation level in all treated groups in respect to control group but there was a decrease in total antioxidant level, and elevation in Acetylcholinesterase activity and Vascular Endothelial Growth Factor level in all treated groups compared to control group. The histological brain damage score was zero for all rats in the control group only, it showed increased mean from group II till group IV. The study demonstrated that Apoptotic Index (determined by the immunohistochemistry) was lowest in the control group and increased significantly from group II through IV.

Conclusion: Dapoxetine administration in rats in large doses for a temporal period affected the brain cells and must be carefully used.

Keywords: Dapoxetine; Brain Damage; Oxidative Stress; Anti-Inflammatory; Lipid Peroxidation.

Introduction

Premature ejaculation (PE) is the most common sexual problem worldwide. Human ejaculation is thought to be controlled by many different physical pathways. In addition to the contribution of the psychological factors to the biological ones which make the pathophysiology of PE even more complex. In the last years, the treatment modalities have consisted of different psychotherapy options. However, discoveries on the central regulation of ejaculation and the therapeutic role of serotonergic agents in PE revolutionized the treatment of this condition. Well-established evidences from the studies have expounded the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in lateness of ejaculation, confirming their role for the therapy of lifelong and gained premature ejaculation (PE) [2].

A modernistic serotonin transporter inhibitor, dapoxetine, has been in proceeding specifically for the curative of PE. Results from placebo-controlled, randomized, multicenter phase III trials have pretended that men with PE extraditing dapoxetine 30 or 60mg long practiced increased intravaginal ejaculatory latency and higher levels of observation through ejaculation and gratification with sexual intercourse [5, 4]. Dapoxetine was effective when taken unwanted, 1-3 h before intercourse. In dissimilarity, large scale studies of efficacy and safety in men with PE have not been behaved with traditional SSRI antidepressants [5, 6].

Neurotoxicity testing of new complex with the desirable pharmacological effects represents one of the major bottlenecks in drug development since it was time consumed and required of many animal experiments. The neurotoxicity is likely to be the result of a collection of many mechanisms, including oxidative brain
injury, prompting of apoptosis and neuronal harm, neuroglia inflammatory reaction, and lessening neurotransmitter biosynthesis [7]. Therefore, the existent research is the first undertaken to repress neuron inflammation and neuronal apoptosis by means of dapoxetine toxicity in the empirical animal model.

**Material and Method**

**Experimental Animal Design**

Forty male albino rats weighing average of 150 g were preserved in the laboratory under steady conditions of temperature (24 ± 2°C) at minimum one week before and through the empirical work, being kept on a standard diet and water, were ready ad-libitum. The animals were preserved in harmony with the rules described by the faculty of Science and study was suitable by Animal Ethics Committee of Fayoum University, Egypt. The rats were divided at random into three empirical study groups (GII, GIII and GIV) and one control group (GI) of 10 rats each. The study groups were daily took dapoxetine hydrochloride (Inspire Pharmaceutical Company, IPC Pharma, Cairo, Egypt) at doses of 2.0, 4.0 or 8.0 mg per kg body weight [8] (every dose for each group) 1 in 0.5 ml saline, while the controls were on 0.5 ml saline. All were kept for 60 days. At the end of the experimental period, animals were killed and the whole brain of each animal was rapidly removed, thoroughly washed with isotonic saline, dried on filter paper and then weighed. Each brain was sagittally split into two halves. One half of each brain was instantly homogenized to give 10% (w/v) homogenate in ice-cold medium containing 50 mM Tris-HCl (pH 7.4) and 300 mM sucrose [9]. The homogenate was centrifuged at 1800 ³g for 10 min at 4°C. The supernatant (10%) was detached and stored at -70°C for biochemical analyses. The second half of each brain was preserved in 10% buffered formalin for histopathological and immunohistochemical examination.

**Biochemical Assays**

Brain lipid peroxidation was estimated by malondialdehyde (MDA) via use of thiobarbituric acid (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) [10]. Total antioxidant status (TAS) was predestined by a colorimetric method rely on the capability of brain antioxidants to inhibit the production of thiobarbituric acid reactive substances (TBARS). TBARS are output following a Fenton-type reaction [11].

Brain acetylcholinesterase activity (AChE) was decided colorimetrically using a kit provided by Sigma-Aldrich (St Louis, MO, USA) [12]. Brain tumour necrosis factor alpha (TNF-α) [13] concentricity was evaluated in the brain homogenate using a rat TNF-α ELISA technique using human TNF-αELISA kit from Orleng Co., Vantaa FINLAND. Brain derived neurotrophic factor (BDNF) was measured by ELISA technicality using [14] kit from RayBiotech Co., USA. Brain vascular endothelial growth factor (VEGF) was evaluated by ELISA steps using [15] a kit purchased from Invitrogen Co., CAMARILLO, and VENTURA, California, USA. Brain (IL-1β) was measured by ELISA steps [16] using a kit from Assay Pro-USA.

**Histopathology and Immunohistochemistry Studies**

Paraffin section (5μm in thickness) was prepared from fixed brain halves for processing the histological and immunohistochemical studies.

For general histology and evaluation of the brains' status; sections were stained with haematoxylin and Eosin (H&E). Estimate of tissue alterations in 20 various fields for each section was conducted by the pathologist who was insensible of the treatment. Histopathological brain damage was scored by grading neuronal necrosis, neurophagia, neuronal edema, vascular congestion, focal hemorrhage and perivascular edema with a maximum score of 18. Each modulation was scored as: 0, absent or very rare; 1, mild; 2, moderate; or 3, severe [17].

For immunohistochemistry using BAX antibodies deparaffinized, rehydrated sections were heated in a microwave oven in 10 mmol/L citrate buffer (PH 6) for antigen retrieval. Sections were in gloriouised in 0.3% H₂O₂ in methanol to block endogenous peroxidase and were pre-incubated with normal mouse or rabbit serum to block nonspecific binding of antibodies. The sections were then incubated with primary antibody. The avidin-biotin-peroxidase-complex manner was used for discovery, with diaminobenzidine tetrachloride as the chromogen. The primary antibody used was rabbit monoclonal BAX antibody (ab32503) (1:250; abcam, USA). As a negative control for immunostaining, the second antibody was used without the first antibody.

Scoring of IHC stained cortical neurons was done under light microscopy. Brown immunostaining of cytoplasm for Bax was considered as positive apoptotic neuronal cells. Semi-quantification analysis of the apoptotic index (AI) was decided by counting a total of at least 1000 cells per slide subdivided in 10 fields chosen at random x 400 magnification. AI% = [number of positive cells/total number of calculated cells] x 100 is the percentage of positive cells in 1000 cells [18].

**Statistical Analysis**

Equal variance between the groups was first checked using the Levene’s test for homogeneity of variances and statistical analysis of the difference between the mean values was carried out using one-way analysis of variance (ANOVA) followed by the least significant difference (LSD) test for multiple comparisons. SPSS statistical software 22.0 for Windows (SPSS, Inc., Chicago, IL, USA) was used for all analyses. A value of p < 0.05 was considered statistically significant for all tests.

**Results**

**Biochemical Results**

The records in Table (1) showed a significant increase (p ≤ 0.001) in lipid peroxidation level (MDA) in all treated groups compared to the control group. Also, the study illustrated a significant decrease (p ≤ 0.001) in total antioxidant level in all treated groups in respect to control group but no significant change between group III and group IV (p = 0.211).

Table (2) showed a significant increase (p ≤ 0.001) in TNF-α level in all treated groups compared to control group. There was a significant elevation (p ≤ 0.001) in IL-1β level in all treated groups compared to control group but no significant change between group III and group IV (p = 0.521). Acetylcholinesterase activity
Table 1. Mean ± S.D. of plasma MDA and Total Antioxidant in all Different Groups.

<table>
<thead>
<tr>
<th>Groups Parameter</th>
<th>Group I (n=10) control</th>
<th>Group II (n=10) 2 mg/kg</th>
<th>Group III (n=10) 4 mg/kg</th>
<th>Group IV (n=10) 8 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA (nmol/mg protein)</td>
<td>18.59 ± 1.51</td>
<td>22.54 ± 1.79&lt;sup&gt;a&lt;/sup&gt;</td>
<td>26.17 ± 2.05&lt;sup&gt;b&lt;/sup&gt;</td>
<td>30.91 ± 1.71&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>TAO(μmol/mg protein)</td>
<td>17.34 ± 2.21</td>
<td>14.98 ± 1.33&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.45 ± 1.14&lt;sup&gt;b&lt;/sup&gt;</td>
<td>11.47 ± 2.09&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

- Significant at P value ≤ 0.05, p > 0.05 is considered non-significant (NS).
- <sup>a</sup>Significant P value versus control group (group I).
- <sup>b</sup>Significant P value versus group III.

Table 2. Mean ± S.D. of Plasma TNF-α, BDNF, VEGF and Acetylcholinesterase Activity in all Different Groups.

<table>
<thead>
<tr>
<th>Groups Parameter</th>
<th>Group I (n=10) control</th>
<th>Group II (n=10) 2 mg/kg</th>
<th>Group III (n=10) 4 mg/kg</th>
<th>Group IV (n=10) 8 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>TNF-α (pg/ mg protein)</td>
<td>195.48 ± 7.86</td>
<td>224.62 ± 4.84&lt;sup&gt;a&lt;/sup&gt;</td>
<td>243.35 ± 4.51&lt;sup&gt;b&lt;/sup&gt;</td>
<td>296.94 ± 6.11&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>IL-1β (pg/ mg protein)</td>
<td>105.41 ± 6.51</td>
<td>125.65 ± 5.98&lt;sup&gt;a&lt;/sup&gt;</td>
<td>127.61 ± 7.26&lt;sup&gt;b&lt;/sup&gt;</td>
<td>129.59 ± 6.11&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>BDNF (ng/ mg protein)</td>
<td>0.52 ± 0.067</td>
<td>0.39 ± 0.046&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.32 ± 0.021&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.301 ± 0.029&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>VEGF (pg/ mg protein)</td>
<td>295.56 ± 4.86</td>
<td>345.67 ± 10.36&lt;sup&gt;a&lt;/sup&gt;</td>
<td>356.44 ± 8.19&lt;sup&gt;b&lt;/sup&gt;</td>
<td>384.73 ± 10.32&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>Acetylcholinesterase activity (U/ mg protein)</td>
<td>18.85 ± 1.54</td>
<td>22.75 ± 3.51&lt;sup&gt;a&lt;/sup&gt;</td>
<td>25.97 ± 2.55&lt;sup&gt;b&lt;/sup&gt;</td>
<td>34.37 ± 5.61&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>Acetylcholine (nmol/mg protein)</td>
<td>0.0852 ± 0.0094</td>
<td>0.064 ± 0.01&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.048 ± 0.013&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.042 ± 0.007&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

- Significant at P value ≤ 0.05, p > 0.05 is considered non-significant (NS).
- <sup>a</sup>Significant P value versus control group (group I).
- <sup>b</sup>Significant P value versus group III.

Histopathological and Immunohistochemistry Results

Examination of H&E stained slides of rat brains (Figure 1) revealed normal brain histology in the control group (Group I), neuronal necrosis started to appear in cerebral cortices in group II (Mean ± SD = 2.8 ± 0.422) and scored 3 in all rats in groups III and IV. Also, neuropathia appeared in group II (Mean ± SD = 1.8 ± 0.422) and scored 3 in all rats in groups III and IV. Neuronal edema was noticed only in group IV (Mean ± SD = 1.9 ± 0.316). Vascular congestion was noticed in all treated groups; (Mean ± SD = 0.9 ± 0.316 and 2.8 ± 0.422 for groups II and III respectively), while the score was 3 for all rats in group IV. Focal hemorrhage was present in groups III and IV only and all rats in both groups scored 1. Perivascular edema was noticed in group IV only (Mean ± SD = 1.8 ± 0.422). The brain damage score was zero for all rats in the control group only, it showed increased mean from group II till group IV (Table 3). The existent study demonstrated that AI (determined by the immunohistochemistry of BAX) was lowest in the control group and increased significantly from group II through IV (Table 3 and Figure 2).

Relation between Biochemical and Immunohistochemical Results

In group IV there was a negative correlation between the apoptotic index (BAX immunostaining) and the total antioxidants (Figure 3), and there was a positive correlation between BAX immunostaining and MDA in Group II (Figure 4).

Discussion

Dapoxetine is a fast-acting SSRI that is used to treat PE and it is often considered as the first line drug therapy [19]. It is not approved for use in the USA and paroxetine has been used as it has a relatively greater efficacy in delaying ejaculation [20]. The exist-
ent study recorded for the first time that dapoxetine motivated oxidative brain cell injury. The brain is more exposed to oxidative stress than any other organ due to its large oxygen consumption, high lipid content, and low mitotic rate and antioxidant levels [21]. Different proteins are involved in the regulation of programmed cell death. However, the importance of apoptosis in toxicology has been underestimated given the difficulty of identifying apoptotic cells [22]. Some members of the Bcl family, such as Bcl-2 are known anti-apoptotic proteins. Whereas, the cytoplasmic expression of Bax is pro-apoptotic that enhance apoptosis [23].

The results showed that a significant rise in TNF-α level in all treated groups compared to control group, this is agreed by other research studied aluminum intoxication in rats and reported an elevation in brain Caspase-3 and TNF-α levels, and this was reflected histologically, as increased brain apoptosis, severe degenerations of cerebral cortex neurons and small pyramidal cells of the hippocampus [24] which is also similar to the existent histologic and immunohistochemical results. Also, another research reported an increase in the brain level of pro-inflammatory molecules, such as TNF-α, IL-1β in rat group treated with arsenic in respect to the normal control group. This happened because arsenic induced the production of free radicals that cause destruction to lipid, protein, and DNA of the body [25].

The brain-derived neurotrophic factor (BDNF) is the basic regulate element for the existence and distinction of eclectic populations of neurons during development. It is synthesised preponderantly in the CNS by neurons, and is highly be expressed in the hippocampus and cortex, two brain area which are recognized to be important for education and memory [26]. The existent study showed a significant decrease (BDNF) level in all dapoxetine

Table 3. Mean ± S.D. of rat brain damage score and BAX immune histochemistry.

<table>
<thead>
<tr>
<th>Group Parameter</th>
<th>Group I (N=10) Control</th>
<th>Group II (N=10) 2 mg/kg</th>
<th>Group III (N=10) 4mg/kg</th>
<th>Group IV (N=10) 8 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain damage score</td>
<td>0</td>
<td>5.3 ± 0.949a</td>
<td>9.8 ± 0.422a</td>
<td>13.7 ± 0.483ab</td>
</tr>
<tr>
<td>Bax Immunohistochemistry</td>
<td>2.05 ± 0.217</td>
<td>8.89 ± 0.871a</td>
<td>15.75 ± 0.802a</td>
<td>17.28 ± 1.069ab</td>
</tr>
</tbody>
</table>

• Significant at P value ≤ 0.05.
• a Significant P value versus control group (Group I).
• b Significant P value versus group III.
Figure 2. BAX immunohistochemical staining of rat cerebral cortices from different groups (X400); negative staining in the control group and cytoplasmic staining (arrows) in the rest of groups.

Figure 3. A negative correlation in group IV between Bax immunostaining and Total antioxidants (p = 0.024 & r = -0.702).

Figure 4. A positive correlation in group II between Bax immunostaining and MDA (p = 0.021 & r = 0.711).
treated groups in comparison to control group but no significant change between group III and group IV, the results that go with a research that has been recorded a reduction in expression of BDNF in aluminium intoxication, that keeps normal neuronal circuits in the brain, and declared that it played a significant role in the development of plentiful neurodegenerative disorders [24]. The current research also coincided with another research of arsenic toxicity that causes brain deterioration and significant reduction in the brain level of BDNF as compared to the normal control group. This inhibition of BDNF was supposed to be a result of the spoilage of the nerve and glial cells in the brain due to the output of reactive oxygen species [25].

The neurotransmitter acetylcholine (Ach) is fundamental for the central and peripheral control of movement, autonomic nervous system function, arranged of sleep, and numerous cognitive procedures including timing, attention, education, and memory [27, 28]. The results of the study also clarified that Acetylcholinesterase activity showed a significant elevation (p ≤ 0.001) in all dapoxetine treated groups as compared to control group, this is similar to what reported by other study which showed an increase in the acetylcholine treated groups as compared to control group, this is similar to what reported by other study which showed an increase in the brain Acetylcholinesterase activity in Alzheimer disease group induced by oral administration of Aluminum chloride (AlCl3) [29].

Conclusion

Our data suggested that dapoxetine administration in rats lead to focal cerebral inflammation in low dose but cause necrosis in increased dose. However, further clinical trials study are still required.

References


